Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploiting the therapeutic implications of KRAS inhibition on tumor immunity.

Cancer cell - 11 Mar 2024

Molina-Arcas Miriam, Downward Julian

Abstract excerpt

Over the past decade, RAS oncogenic proteins have transitioned from being deemed undruggable to having two clinically approved drugs, with several more in advanced stages of development. Despite the initial benefit of KRAS-G12C inhibitors for patients with tumors harboring this mutation, the rapid emergence of drug resistance underscores the urgent need to synergize these inhibitors with other therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to KRAS gene
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy and Immune Responses

Share to Mutation

Share to Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Tumor Microenvironment

Source

Identifiers

PMID: 38471457
DOI: 10.1016/j.ccell.2024.02.012

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploiting the therapeutic implications of KRAS inhibition on tumor immunity.PMID 38471457Read ↗

KRAS G12C inhibition and innate immune targeting.Semantic proximity Read ↗

Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy.Semantic proximity Read ↗

Kras and Tumor Immunity: Friend or Foe?Semantic proximity Read ↗

KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of ImmunotherapySemantic proximity Read ↗

Unveiling the role of KRAS in tumor immune microenvironment.Semantic proximity Read ↗

Immune modulatory effects of oncogenic KRAS in cancerSemantic proximity Read ↗

Targeting KRAS in colorectal cancer immunotherapy: rationale, challenges and future directions.Semantic proximity Read ↗

RAS signaling and immune cells: a sinister crosstalk in the tumor microenvironmentSemantic proximity Read ↗

Mechanistic Foundations of KRAS‐Driven Tumor Ecosystems: Integrating Crosstalk among Immune, Metabolic, Microbial, and Stromal MicroenvironmentSemantic proximity Read ↗

KRAS and MYC synergistic inhibition: a powerful strategy targeting KRAS-mutant cancers.Semantic proximity Read ↗

Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapySemantic proximity Read ↗

Cancer vaccines: Targeting KRAS-driven cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.